Key result
Adjuvant mitotane was associated with a significantly shorter disease-free interval (P=0.0055) and a lower 2-year survival rate (43% vs 100%) compared to no or discontinued therapy.
Why the study?
Does adjuvant mitotane improve time to recurrence and survival in patients with localized or regional adrenocortical cancer?
Population
19 patients with localized or regional adrenocortical cancer at the time of surgery, registered at M.D…
Comparison
Adjuvant mitotane administered postoperatively vs No mitotane (n=6)
Design
Cohort
Follow-up
at least 12 months
Authors
Loading...
Adjuvant mitotane warrants caution in localized adrenocortical cancer; leaves open its role pending randomized trials.
Cohort (n=19)
No
Does adjuvant mitotane improve time to recurrence and survival in patients with localized or regional adrenocortical cancer?
p-value: p=0.0055
Adjuvant mitotane does not appear to improve disease-free interval or survival in patients with localized or regional adrenocortical cancer, and may be associated with worse outcomes.
Vassilopoulou‐Sellin et al. (1993) conducted a cohort in localized or regional adrenocortical cancer (n=19). Adjuvant mitotane vs. No mitotane or discontinued mitotane was evaluated on time to recurrence (p=0.0055). Adjuvant mitotane was associated with a significantly shorter disease-free interval (P=0.0055) and a lower 2-year survival rate (43% vs 100%) compared to no or discontinued therapy.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: